| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) through any online brokerage.
Other companies in Alnylam Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Alnylam Pharmaceuticals has a consensus price target of $418.44.
The stock price for Alnylam Pharmaceuticals (NASDAQ: ALNY) is $224.61 last updated October 6, 2026 at 6:51 PM EDT.
There are no upcoming dividends for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
